On February 26, 2026, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the approval of the mCOMBRIAX vaccine from Moderna Biotech Spain S.L.[1] This vaccine is intended to prevent influenza and COVID-19 disease caused by the SARS-CoV-2 virus in adults over 50 years of age.[1] mCOMBRIAX is an mRNA vaccine that contains genetic information encoding proteins against seasonal influenza types A (H1N1 and H3N2) and B (Victoria lineage) and parts of the SARS-CoV-2 protein.[1] The vaccine will be available as an injection in prefilled syringes.[1] If approved, mCOMBRIAX would become the first combination vaccine against COVID-19 and influenza to receive regulatory approval worldwide.[1] A positive CHMP opinion is the next step in the approval process, with the European Commission issuing the final decision.